• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

致癌性Kit通过Stat5/PI3激酶信号级联反应控制肿瘤性肥大细胞的生长。

Oncogenic Kit controls neoplastic mast cell growth through a Stat5/PI3-kinase signaling cascade.

作者信息

Harir Noria, Boudot Cédric, Friedbichler Katrin, Sonneck Karoline, Kondo Rudin, Martin-Lannerée Séverine, Kenner Lukas, Kerenyi Marc, Yahiaoui Saliha, Gouilleux-Gruart Valérie, Gondry Jean, Bénit Laurence, Dusanter-Fourt Isabelle, Lassoued Kaïss, Valent Peter, Moriggl Richard, Gouilleux Fabrice

机构信息

Inserm (EMI 351), Faculté de Médecine, Université de Picardie J. Verne, Amiens, France.

出版信息

Blood. 2008 Sep 15;112(6):2463-73. doi: 10.1182/blood-2007-09-115477. Epub 2008 Jun 25.

DOI:10.1182/blood-2007-09-115477
PMID:18579792
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2532813/
Abstract

The D816V-mutated variant of Kit triggers multiple signaling pathways and is considered essential for malignant transformation in mast cell (MC) neoplasms. We here describe that constitutive activation of the Stat5-PI3K-Akt-cascade controls neoplastic MC development. Retrovirally transduced active Stat5 (cS5(F)) was found to trigger PI3K and Akt activation, and to transform murine bone marrow progenitors into tissue-infiltrating MCs. Primary neoplastic Kit D816V(+) MCs in patients with mastocytosis also displayed activated Stat5, which was found to localize to the cytoplasm and to form a signaling complex with PI3K, with consecutive Akt activation. Finally, the knock-down of either Stat5 or Akt activity resulted in growth inhibition of neoplastic Kit D816V(+) MCs. These data suggest that a downstream Stat5-PI3K-Akt signaling cascade is essential for Kit D816V-mediated growth and survival of neoplastic MCs.

摘要

Kit的D816V突变变体可触发多种信号通路,被认为是肥大细胞(MC)肿瘤发生恶性转化所必需的。我们在此描述,Stat5-PI3K-Akt级联的组成性激活控制着肿瘤性MC的发育。发现逆转录病毒转导的活性Stat5(cS5(F))可触发PI3K和Akt激活,并将小鼠骨髓祖细胞转化为组织浸润性MC。肥大细胞增多症患者的原发性肿瘤性Kit D816V(+) MC也显示出激活的Stat5,发现其定位于细胞质,并与PI3K形成信号复合物,随后激活Akt。最后,Stat5或Akt活性的敲低导致肿瘤性Kit D816V(+) MC的生长受到抑制。这些数据表明,下游的Stat5-PI3K-Akt信号级联对于Kit D816V介导的肿瘤性MC的生长和存活至关重要。

相似文献

1
Oncogenic Kit controls neoplastic mast cell growth through a Stat5/PI3-kinase signaling cascade.致癌性Kit通过Stat5/PI3激酶信号级联反应控制肿瘤性肥大细胞的生长。
Blood. 2008 Sep 15;112(6):2463-73. doi: 10.1182/blood-2007-09-115477. Epub 2008 Jun 25.
2
Phosphatidylinositol 3 kinase contributes to the transformation of hematopoietic cells by the D816V c-Kit mutant.磷脂酰肌醇3激酶通过D816V c-Kit突变体促进造血细胞的转化。
Blood. 2001 Sep 1;98(5):1365-73. doi: 10.1182/blood.v98.5.1365.
3
Expression of activated STAT5 in neoplastic mast cells in systemic mastocytosis: subcellular distribution and role of the transforming oncoprotein KIT D816V.活化 STAT5 在系统性肥大细胞增多症中肿瘤性肥大细胞中的表达:转化癌蛋白 KIT D816V 的亚细胞分布和作用。
Am J Pathol. 2009 Dec;175(6):2416-29. doi: 10.2353/ajpath.2009.080953. Epub 2009 Nov 5.
4
Identification of oncostatin M as a STAT5-dependent mediator of bone marrow remodeling in KIT D816V-positive systemic mastocytosis.鉴定出骨基质重塑的 STAT5 依赖性介质——肿瘤坏死因子超家族成员 13,其在 KIT D816V 阳性系统性肥大细胞增多症中。
Am J Pathol. 2011 May;178(5):2344-56. doi: 10.1016/j.ajpath.2011.01.020. Epub 2011 Mar 31.
5
Co-operating STAT5 and AKT signaling pathways in chronic myeloid leukemia and mastocytosis: possible new targets of therapy.慢性粒细胞白血病和肥大细胞增多症中协同作用的STAT5和AKT信号通路:可能的新治疗靶点。
Haematologica. 2014 Mar;99(3):417-29. doi: 10.3324/haematol.2013.098442.
6
The activation loop tyrosine 823 is essential for the transforming capacity of the c-Kit oncogenic mutant D816V.激活环酪氨酸823对于c-Kit致癌突变体D816V的转化能力至关重要。
Oncogene. 2015 Aug 27;34(35):4581-90. doi: 10.1038/onc.2014.383. Epub 2014 Dec 1.
7
Targeting Sphingosine Kinase Isoforms Effectively Reduces Growth and Survival of Neoplastic Mast Cells With D816V-KIT.靶向鞘氨醇激酶同工型可有效抑制携带 D816V-KIT 的肿瘤性肥大细胞的生长和存活。
Front Immunol. 2018 Mar 28;9:631. doi: 10.3389/fimmu.2018.00631. eCollection 2018.
8
CRISPR/Cas9-engineering of HMC-1.2 cells renders a human mast cell line with a single D816V-KIT mutation: An improved preclinical model for research on mastocytosis.CRISPR/Cas9 技术修饰 HMC-1.2 细胞构建具有单一 D816V-KIT 突变的人类肥大细胞系:肥大细胞增多症研究的改良临床前模型。
Front Immunol. 2023 Mar 21;14:1078958. doi: 10.3389/fimmu.2023.1078958. eCollection 2023.
9
Phospho-STAT5 and phospho-Akt expression in chronic myeloproliferative neoplasms.慢性骨髓增殖性肿瘤中磷酸化 STAT5 和磷酸化 Akt 的表达。
Br J Haematol. 2009 Nov;147(4):495-506. doi: 10.1111/j.1365-2141.2009.07870.x. Epub 2009 Aug 31.
10
KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib.在系统性肥大细胞增多症中的肿瘤细胞中,KIT-D816V 不依赖的致癌信号:Lyn 和 Btk 的激活作用以及达沙替尼和博舒替尼的阻断作用。
Blood. 2011 Aug 18;118(7):1885-98. doi: 10.1182/blood-2010-06-289959. Epub 2011 Jun 16.

引用本文的文献

1
Mastocytosis.肥大细胞增多症
Nat Rev Dis Primers. 2025 Apr 24;11(1):30. doi: 10.1038/s41572-025-00611-8.
2
Fedratinib and gandotinib induce apoptosis and enhance the efficacy of tyrosine kinase inhibitors in human mast cells.非达替尼和甘多替尼可诱导人肥大细胞凋亡并增强酪氨酸激酶抑制剂的疗效。
Am J Cancer Res. 2025 Jan 15;15(1):84-98. doi: 10.62347/TYTU4465. eCollection 2025.
3
Exploration of the mechanism of Lithospermum erythrorhizon oil in treating atopic dermatitis based on network pharmacology and experimental validation of the PI3K-Akt pathway regulation.基于网络药理学探讨紫草油治疗特应性皮炎的机制及PI3K-Akt信号通路调控的实验验证
Heliyon. 2025 Jan 10;11(2):e41707. doi: 10.1016/j.heliyon.2025.e41707. eCollection 2025 Jan 30.
4
Management of Advanced Systemic Mastocytosis: Clinical Challenges.晚期系统性肥大细胞增多症的管理:临床挑战
J Blood Med. 2024 Sep 11;15:421-433. doi: 10.2147/JBM.S366367. eCollection 2024.
5
The PI3K-Akt-mTOR and Associated Signaling Pathways as Molecular Drivers of Immune-Mediated Inflammatory Skin Diseases: Update on Therapeutic Strategy Using Natural and Synthetic Compounds.PI3K-Akt-mTOR 及相关信号通路作为免疫介导性炎症性皮肤病的分子驱动因素:天然和合成化合物治疗策略的最新进展。
Cells. 2023 Jun 20;12(12):1671. doi: 10.3390/cells12121671.
6
c-Kit signaling potentiates CAR T cell efficacy in solid tumors by CD28- and IL-2-independent co-stimulation.c-Kit 信号通过 CD28-和 IL-2 非依赖性共刺激增强 CAR T 细胞在实体瘤中的疗效。
Nat Cancer. 2023 Jul;4(7):1001-1015. doi: 10.1038/s43018-023-00573-4. Epub 2023 Jun 19.
7
CRISPR/Cas9-engineering of HMC-1.2 cells renders a human mast cell line with a single D816V-KIT mutation: An improved preclinical model for research on mastocytosis.CRISPR/Cas9 技术修饰 HMC-1.2 细胞构建具有单一 D816V-KIT 突变的人类肥大细胞系:肥大细胞增多症研究的改良临床前模型。
Front Immunol. 2023 Mar 21;14:1078958. doi: 10.3389/fimmu.2023.1078958. eCollection 2023.
8
Targeting Mast Cells in Allergic Disease: Current Therapies and Drug Repurposing.靶向变应性疾病中的肥大细胞:现有疗法和药物再利用。
Cells. 2022 Sep 27;11(19):3031. doi: 10.3390/cells11193031.
9
A Critical Function for the Transcription Factors GLI1 and GLI2 in the Proliferation and Survival of Human Mast Cells.转录因子 GLI1 和 GLI2 在人类肥大细胞增殖和存活中的关键功能。
Front Immunol. 2022 Feb 16;13:841045. doi: 10.3389/fimmu.2022.841045. eCollection 2022.
10
A Deep Insight Into Regulatory T Cell Metabolism in Renal Disease: Facts and Perspectives.深入探讨肾脏疾病中调节性 T 细胞代谢:事实与展望。
Front Immunol. 2022 Feb 17;13:826732. doi: 10.3389/fimmu.2022.826732. eCollection 2022.

本文引用的文献

1
Cytoplasmic localization of phosphorylated STAT5 in human acute myeloid leukemia is inversely correlated with Flt3-ITD.人类急性髓系白血病中磷酸化STAT5的细胞质定位与Flt3-ITD呈负相关。
Blood. 2007 Oct 1;110(7):2775-6. doi: 10.1182/blood-2007-05-090969.
2
Detection of phospho-STAT5 in mast cells: a reliable phenotypic marker of systemic mast cell disease that reflects constitutive tyrosine kinase activation.肥大细胞中磷酸化 STAT5 的检测:系统性肥大细胞疾病的可靠表型标志物,反映组成型酪氨酸激酶激活。
Br J Haematol. 2007 Oct;139(1):31-40. doi: 10.1111/j.1365-2141.2007.06708.x. Epub 2007 Jul 27.
3
Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria.肥大细胞增多症的标准与标准化:关于诊断、治疗建议及反应标准的共识声明
Eur J Clin Invest. 2007 Jun;37(6):435-53. doi: 10.1111/j.1365-2362.2007.01807.x.
4
Constitutive activation of Stat5 promotes its cytoplasmic localization and association with PI3-kinase in myeloid leukemias.Stat5的组成性激活促进其在髓系白血病中的细胞质定位以及与PI3激酶的结合。
Blood. 2007 Feb 15;109(4):1678-86. doi: 10.1182/blood-2006-01-029918. Epub 2006 Oct 12.
5
Stat5 expression is required for IgE-mediated mast cell function.Stat5表达是IgE介导的肥大细胞功能所必需的。
J Immunol. 2006 Sep 1;177(5):3421-6. doi: 10.4049/jimmunol.177.5.3421.
6
STAT5 signaling is required for the efficient induction and maintenance of CML in mice.STAT5信号传导是小鼠中慢性粒细胞白血病有效诱导和维持所必需的。
Blood. 2006 Jun 15;107(12):4917-25. doi: 10.1182/blood-2005-10-4110. Epub 2006 Mar 7.
7
Clarifying the role of Stat5 in lymphoid development and Abelson-induced transformation.阐明Stat5在淋巴细胞发育及阿贝尔森病毒诱导的转化过程中的作用。
Blood. 2006 Jun 15;107(12):4898-906. doi: 10.1182/blood-2005-09-3596. Epub 2006 Feb 21.
8
Mastocytosis in mice expressing human Kit receptor with the activating Asp816Val mutation.表达具有激活型Asp816Val突变的人Kit受体的小鼠中的肥大细胞增多症。
J Exp Med. 2005 Dec 19;202(12):1635-41. doi: 10.1084/jem.20050807. Epub 2005 Dec 13.
9
PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects.PKC412抑制表达KIT基因D816V突变变体的人肿瘤性肥大细胞的体外生长:与AMN107、伊马替尼和克拉屈滨(2CdA)比较及联合用药效果评估。
Blood. 2006 Jan 15;107(2):752-9. doi: 10.1182/blood-2005-07-3022. Epub 2005 Sep 27.
10
Signaling by Kit protein-tyrosine kinase--the stem cell factor receptor.Kit蛋白酪氨酸激酶(干细胞因子受体)介导的信号传导
Biochem Biophys Res Commun. 2005 Nov 11;337(1):1-13. doi: 10.1016/j.bbrc.2005.08.055.